VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q59689174 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010728.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q59689174‏
024 ‎‡a 0000-0003-3209-1392‏ ‎‡2 orcid‏
024 ‎‡a 55674790500‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q59689174‏
100 0 ‎‡a Ricardo Niklas Werner‏ ‎‡c researcher ORCID ID = 0000-0003-3209-1392‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Ricardo Niklas Werner‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's 2019 IUSTI-Europe guideline for the management of anogenital warts‏
670 ‎‡a Author's Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis.‏
670 ‎‡a Author's Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials.‏
670 ‎‡a Author's Antibiotic resistance in acne.‏
670 ‎‡a Author's Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study.‏
670 ‎‡a Author's Can physician's self-estimates be used as a valid instrument to determine prescription frequencies of anti-psoriatic drugs? Comparison of the results of a cross-sectional study using self-estimates with actual prescription behavior documented in a c‏
670 ‎‡a Author's Chronic inducible urticaria: a systematic review of treatment options.‏
670 ‎‡a Author's Current guidelines in dermatology: A selection of clinically relevant recommendations‏
670 ‎‡a Author's Diagnostics and management of herpes zoster ophthalmicus‏
670 ‎‡a Author's Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis‏
670 ‎‡a Author's European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis.‏
670 ‎‡a Author's European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment.‏
670 ‎‡a Author's European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version‏
670 ‎‡a Author's European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.‏
670 ‎‡a Author's European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.‏
670 ‎‡a Author's Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version.‏
670 ‎‡a Author's Executive summary: Methods and evidence report for the evidence - and consensus- based (S3) Guideline for the definition, classification, diagnosis, and management of urticaria - revision and update 2017.‏
670 ‎‡a Author's Herpes Zoster – Empfehlungen der konsensbasierten Europäischen Leitlinie.‏
670 ‎‡a Author's Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis‏
670 ‎‡a Author's Knowledge and use of HIV pre-exposure prophylaxis among men who have sex with men in Berlin - A multicentre, cross-sectional survey‏
670 ‎‡a Author's Management of antithrombotic agents in dermatologic surgery before and after publication of the corresponding German evidence-based guideline.‏
670 ‎‡a Author's Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum‏
670 ‎‡a Author's Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.‏
670 ‎‡a Author's Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--EDF in cooperation with EADV and IPC.‏
670 ‎‡a Author's Methods report on the development of the European evidence-based‏
670 ‎‡a Author's Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne - update 2016‏
670 ‎‡a Author's Methods Report: Update of the German S3 Guideline for the Treatment of Psoriasis vulgaris‏
670 ‎‡a Author's Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis‏
670 ‎‡a Author's Online consensus conferences for clinical guidelines development - a survey among participants from the International Guidelines for the Treatment of Actinic Keratosis‏
670 ‎‡a Author's Prioritising topics in guideline development - Results of a two-phase online survey of dermatologist members of the EADV‏
670 ‎‡a Author's Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN).‏
670 ‎‡a Author's S2k guideline: HPV-associated lesions of the external genital region and the anus - anogenital warts and precancerous lesions of the vulva, the penis, and the peri- and intra-anal skin (short version).‏
670 ‎‡a Author's S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 1‏
670 ‎‡a Author's S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2‏
670 ‎‡a Author's S2k-Leitlinie: HPV-assoziierte Läsionen der äußeren Genitalregion und des Anus - Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (Kurzfassung).‏
670 ‎‡a Author's S2k-Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen - Kurzfassung Teil 1‏
670 ‎‡a Author's S2k-Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen - Kurzfassung Teil 2‏
670 ‎‡a Author's Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis‏
670 ‎‡a Author's 'Surprisingly little evidence' on how best to treat actinic keratosis in organ transplant recipients‏
670 ‎‡a Author's The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update‏
670 ‎‡a Author's The natural history of actinic keratosis: a systematic review.‏
670 ‎‡a Author's The quality of European dermatological guidelines: critical appraisal of the quality of EDF guidelines using the AGREE II instrument‏
670 ‎‡a Author's The Treatment of Scabies.‏
670 ‎‡a Author's Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals‏
670 ‎‡a Author's Topical treatments for scalp psoriasis‏
670 ‎‡a Author's Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review‏
670 ‎‡a Author's Treating actinic keratosis.‏
670 ‎‡a Author's Umgang mit Antithrombotika bei Operationen an der Haut vor und nach Publikation der entsprechenden S3-Leitlinie.‏
670 ‎‡a Author's Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.‏
909 ‎‡a (scopus) 55674790500‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000332091392‏ ‎‡9 1‏
919 ‎‡a methodsreportupdateofthegermans3guidelineforthetreatmentofpsoriasisvulgaris‏ ‎‡A Methods Report: Update of the German S3 Guideline for the Treatment of Psoriasis vulgaris‏ ‎‡9 1‏
919 ‎‡a eaaciga2lenedfwaoguidelineforthedefinitionclassificationdiagnosisandmanagementofurticariathe2017revisionandupdate‏ ‎‡A The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update‏ ‎‡9 1‏
919 ‎‡a naturalhistoryofactinickeratosisasystematicreview‏ ‎‡A The natural history of actinic keratosis: a systematic review.‏ ‎‡9 1‏
919 ‎‡a topicaltreatmentsforscalppsoriasissummaryofacochranesystematicreview‏ ‎‡A Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review‏ ‎‡9 1‏
919 ‎‡a topicaltreatmentsforscalppsoriasis‏ ‎‡A Topical treatments for scalp psoriasis‏ ‎‡9 1‏
919 ‎‡a timeuntilonsetofactionwhentreatingpsoriaticarthritismetaanalysisandnovelapproachofgeneratingconfidenceintervals‏ ‎‡A Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals‏ ‎‡9 1‏
919 ‎‡a treatmentofscabies‏ ‎‡A The Treatment of Scabies.‏ ‎‡9 1‏
919 ‎‡a qualityofeuropeandermatologicalguidelinescriticalappraisalofthequalityofedfguidelinesusingtheagree2instrument‏ ‎‡A The quality of European dermatological guidelines: critical appraisal of the quality of EDF guidelines using the AGREE II instrument‏ ‎‡9 1‏
919 ‎‡a herpeszosterempfehlungenderkonsensbasierteneuropaischenleitlinie‏ ‎‡A Herpes Zoster – Empfehlungen der konsensbasierten Europäischen Leitlinie.‏ ‎‡9 1‏
919 ‎‡a incidenceofsexuallytransmittedinfectionsinmenwhohavesexwithmenandwhoareatsubstantialriskofhivinfectionametaanalysisofdatafromtrialsandobservationalstudiesofhivpreexposureprophylaxis‏ ‎‡A Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis‏ ‎‡9 1‏
919 ‎‡a knowledgeanduseofhivpreexposureprophylaxisamongmenwhohavesexwithmeninberlinamulticentrecrosssectionalsurvey‏ ‎‡A Knowledge and use of HIV pre-exposure prophylaxis among men who have sex with men in Berlin - A multicentre, cross-sectional survey‏ ‎‡9 1‏
919 ‎‡a managementofantithromboticagentsindermatologicsurgerybeforeandafterpublicationofthecorrespondinggermanevidencebasedguideline‏ ‎‡A Management of antithrombotic agents in dermatologic surgery before and after publication of the corresponding German evidence-based guideline.‏ ‎‡9 1‏
919 ‎‡a europeans3guidelinesonthesystemictreatmentofpsoriasisvulgarisupdate2015shortversionedfincooperationwitheadvandipc‏ ‎‡A European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.‏ ‎‡9 1‏
919 ‎‡a europeans3guidelineonthesystemictreatmentofpsoriasisvulgarisupdateapremilastandsecukinumabedfincooperationwitheadvandipc‏ ‎‡A European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.‏ ‎‡9 1‏
919 ‎‡a selfadministeredinterventionsforanogenitalwartsinimmunocompetentpatientsasystematicreviewandmetaanalysis‏ ‎‡A Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis‏ ‎‡9 1‏
919 ‎‡a evidenceandconsensusbaseds3guidelinesforthetreatmentofactinickeratosisinternationalleagueofdermatologicalsocietiesincooperationwiththeeuropeandermatologyforumshortversion‏ ‎‡A Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version.‏ ‎‡9 1‏
919 ‎‡a europeanevidencebaseds3guidelineforthetreatmentofacneupdate2016shortversion‏ ‎‡A European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version‏ ‎‡9 1‏
919 ‎‡a europeanconsensusbaseds2kguidelineonthemanagementofherpeszosterguidedbytheeuropeandermatologyforumedfincooperationwiththeeuropeanacademyofdermatologyandvenereologyeadvpart2treatment‏ ‎‡A European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment.‏ ‎‡9 1‏
919 ‎‡a europeanconsensusbaseds2kguidelineonthemanagementofherpeszosterguidedbytheeuropeandermatologyforumedfincooperationwiththeeuropeanacademyofdermatologyandvenereologyeadvpart1diagnosis‏ ‎‡A European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis.‏ ‎‡9 1‏
919 ‎‡a efficacyandsafetyofsystemiclongtermtreatmentsformoderatetoseverepsoriasisasystematicreviewandmetaanalysis‏ ‎‡A Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis‏ ‎‡9 1‏
919 ‎‡a diagnosticsandmanagementofherpeszosterophthalmicus‏ ‎‡A Diagnostics and management of herpes zoster ophthalmicus‏ ‎‡9 1‏
919 ‎‡a currentguidelinesindermatologyaselectionofclinicallyrelevantrecommendations‏ ‎‡A Current guidelines in dermatology: A selection of clinically relevant recommendations‏ ‎‡9 1‏
919 ‎‡a surprisinglylittleevidenceonhowbesttotreatactinickeratosisinorgantransplantrecipients‏ ‎‡A 'Surprisingly little evidence' on how best to treat actinic keratosis in organ transplant recipients‏ ‎‡9 1‏
919 ‎‡a chronicinducibleurticariaasystematicreviewoftreatmentoptions‏ ‎‡A Chronic inducible urticaria: a systematic review of treatment options.‏ ‎‡9 1‏
919 ‎‡a canphysiciansselfestimatesbeusedasavalidinstrumenttodetermineprescriptionfrequenciesofantipsoriaticdrugscomparisonoftheresultsofacrosssectionalstudyusingselfestimateswithactualprescriptionbehaviordocumentedina100‏ ‎‡A Can physician's self-estimates be used as a valid instrument to determine prescription frequencies of anti-psoriatic drugs? Comparison of the results of a cross-sectional study using self-estimates with actual prescription behavior documented in a c‏ ‎‡9 1‏
919 ‎‡a barrierstotheprescriptionofsystemictherapiesformoderatetoseverepsoriasisamultinationalcrosssectionalstudy‏ ‎‡A Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study.‏ ‎‡9 1‏
919 ‎‡a antibioticresistanceinacne‏ ‎‡A Antibiotic resistance in acne.‏ ‎‡9 1‏
919 ‎‡a anogenitalwartsandotherhpvassociatedanogenitallesionsinthehivpositivepatientasystematicreviewandmetaanalysisoftheefficacyandsafetyofinterventionsassessedincontrolledclinicaltrials‏ ‎‡A Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials.‏ ‎‡9 1‏
919 ‎‡a methodsreportonthedevelopmentoftheeuropeanevidencebaseds3guidelineforthetreatmentofacneupdate‏ ‎‡A Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne - update 2016‏ ‎‡9 1‏
919 ‎‡a methodsandresultsreportevidenceandconsensusbaseds3guidelinesforthetreatmentofactinickeratosisinternationalleagueofdermatologicalsocietiesincooperationwiththeeuropeandermatologyforum‏ ‎‡A Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis -International League of Dermatological Societies in cooperation with the European Dermatology Forum‏ ‎‡9 1‏
919 ‎‡a methodsreporteuropeans3guidelineonthesystemictreatmentofpsoriasisvulgarisupdateapremilastandsecukinumabedfincooperationwitheadvandipc‏ ‎‡A Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.‏ ‎‡9 1‏
919 ‎‡a methodsreporteuropeans3guidelinesonthesystemictreatmentofpsoriasisvulgarisupdate2015edfincooperationwitheadvandipc‏ ‎‡A Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--EDF in cooperation with EADV and IPC.‏ ‎‡9 1‏
919 ‎‡a methodsreportonthedevelopmentoftheeuropeanevidencebased‏ ‎‡A Methods report on the development of the European evidence-based‏ ‎‡9 1‏
919 ‎‡a adjuvanttreatmentofanogenitalwartswithsystemicinterferonasystematicreviewandmetaanalysis‏ ‎‡A Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis.‏ ‎‡9 1‏
919 ‎‡a 2019iustieuropeguidelineforthemanagementofanogenitalwarts‏ ‎‡A 2019 IUSTI-Europe guideline for the management of anogenital warts‏ ‎‡9 1‏
919 ‎‡a s2kleitliniezurtherapiederpsoriasisbeikindernundjugendlichenkurzfassungteil2‏ ‎‡A S2k-Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen - Kurzfassung Teil 2‏ ‎‡9 1‏
919 ‎‡a s2kleitliniezurtherapiederpsoriasisbeikindernundjugendlichenkurzfassungteil1‏ ‎‡A S2k-Leitlinie zur Therapie der Psoriasis bei Kindern und Jugendlichen - Kurzfassung Teil 1‏ ‎‡9 1‏
919 ‎‡a executivesummarymethodsandevidencereportfortheevidenceandconsensusbaseds3guidelineforthedefinitionclassificationdiagnosisandmanagementofurticariarevisionandupdate‏ ‎‡A Executive summary: Methods and evidence report for the evidence - and consensus- based (S3) Guideline for the definition, classification, diagnosis, and management of urticaria - revision and update 2017.‏ ‎‡9 1‏
919 ‎‡a s2kleitliniehpvassoziiertelasionenderausserengenitalregionunddesanusgenitalwarzenundkrebsvorstufendervulvadespenisundderperiundintraanalenhautkurzfassung‏ ‎‡A S2k-Leitlinie: HPV-assoziierte Läsionen der äußeren Genitalregion und des Anus - Genitalwarzen und Krebsvorstufen der Vulva, des Penis und der peri- und intraanalen Haut (Kurzfassung).‏ ‎‡9 1‏
919 ‎‡a s2kguidelinesforthetreatmentofpsoriasisinchildrenandadolescentsshortversionpart2‏ ‎‡A S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2‏ ‎‡9 1‏
919 ‎‡a s2kguidelinesforthetreatmentofpsoriasisinchildrenandadolescentsshortversionpart1‏ ‎‡A S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 1‏ ‎‡9 1‏
919 ‎‡a s2kguidelinehpvassociatedlesionsoftheexternalgenitalregionandtheanusanogenitalwartsandprecancerouslesionsofthevulvathepenisandtheperiandintraanalskinshortversion‏ ‎‡A S2k guideline: HPV-associated lesions of the external genital region and the anus - anogenital warts and precancerous lesions of the vulva, the penis, and the peri- and intra-anal skin (short version).‏ ‎‡9 1‏
919 ‎‡a reportfromthekickoffmeetingofthecochraneskingroupcoreoutcomesetinitiativecsgcousin‏ ‎‡A Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN).‏ ‎‡9 1‏
919 ‎‡a prioritisingtopicsinguidelinedevelopmentresultsofa2phaseonlinesurveyofdermatologistmembersoftheeadv‏ ‎‡A Prioritising topics in guideline development - Results of a two-phase online survey of dermatologist members of the EADV‏ ‎‡9 1‏
919 ‎‡a whichantipsoriaticdrughasthefastestonsetofactionsystematicreviewontherapidityoftheonsetofaction‏ ‎‡A Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.‏ ‎‡9 1‏
919 ‎‡a umgangmitantithrombotikabeioperationenanderhautvorundnachpublikationderentsprechendens3leitlinie‏ ‎‡A Umgang mit Antithrombotika bei Operationen an der Haut vor und nach Publikation der entsprechenden S3-Leitlinie.‏ ‎‡9 1‏
919 ‎‡a treatingactinickeratosis‏ ‎‡A Treating actinic keratosis.‏ ‎‡9 1‏
919 ‎‡a onlineconsensusconferencesforclinicalguidelinesdevelopmentasurveyamongparticipantsfromtheinternationalguidelinesforthetreatmentofactinickeratosis‏ ‎‡A Online consensus conferences for clinical guidelines development - a survey among participants from the International Guidelines for the Treatment of Actinic Keratosis‏ ‎‡9 1‏
919 ‎‡a offlabelprescriptionsanddecisionsonreimbursementrequestsingermanyaretrospectiveanalysis‏ ‎‡A Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2017‏ ‎‡9 2‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000023232702‏
996 ‎‡2 RERO|A003968661‏
996 ‎‡2 LC|nb2016019729‏
996 ‎‡2 SUDOC|030177065‏
996 ‎‡2 DNB|142283878‏
996 ‎‡2 DNB|1231631872‏
996 ‎‡2 SUDOC|240092422‏
996 ‎‡2 BNF|12164690‏
996 ‎‡2 DNB|1124703624‏
996 ‎‡2 NII|DA1309888X‏
996 ‎‡2 PLWABN|9810628575805606‏
996 ‎‡2 NTA|07146381X‏
996 ‎‡2 LC|no2007038445‏
996 ‎‡2 LC|n 85085858‏
996 ‎‡2 NTA|291281052‏
996 ‎‡2 DNB|141361786‏
996 ‎‡2 ISNI|000000011469788X‏
996 ‎‡2 BAV|495_211029‏
996 ‎‡2 NKC|xx0241949‏
996 ‎‡2 KRNLK|KAC200411312‏
996 ‎‡2 BNC|981058596088506706‏
996 ‎‡2 ISNI|0000000029476636‏
996 ‎‡2 DNB|138506574‏
996 ‎‡2 NUKAT|n 2015066235‏
996 ‎‡2 DNB|136713297‏
996 ‎‡2 NDL|00844603‏
996 ‎‡2 NTA|364069910‏
996 ‎‡2 BIBSYS|90560514‏
996 ‎‡2 NSK|000448636‏
996 ‎‡2 SUDOC|241120950‏
996 ‎‡2 NKC|mzk2009533437‏
996 ‎‡2 DNB|1122222017‏
996 ‎‡2 RERO|A011119675‏
996 ‎‡2 CAOONL|ncf10701624‏
996 ‎‡2 DNB|1013861051‏
996 ‎‡2 LC|no2022034762‏
996 ‎‡2 PLWABN|9810530344905606‏
996 ‎‡2 ISNI|0000000020615337‏
996 ‎‡2 DNB|1330637070‏
996 ‎‡2 NLA|000035771622‏
996 ‎‡2 BNE|XX1338813‏
996 ‎‡2 LC|n 81085081‏
996 ‎‡2 PLWABN|9810622239305606‏
996 ‎‡2 J9U|987007269825905171‏
996 ‎‡2 BIBSYS|13049508‏
996 ‎‡2 NUKAT|n 2009106632‏
996 ‎‡2 BNF|12462589‏
996 ‎‡2 LC|n 2002107982‏
996 ‎‡2 DNB|104448747X‏
996 ‎‡2 ISNI|000000010928671X‏
996 ‎‡2 SUDOC|03380222X‏
996 ‎‡2 DNB|133225011‏
996 ‎‡2 RERO|A013457673‏
996 ‎‡2 LIH|LNB:_b_A_a_;=BU‏
996 ‎‡2 NTA|258457678‏
996 ‎‡2 BIBSYS|4095766‏
996 ‎‡2 RERO|A009945638‏
996 ‎‡2 ISNI|0000000355547719‏
996 ‎‡2 DNB|130685747‏
996 ‎‡2 LC|n 79131046‏
996 ‎‡2 RERO|A017993370‏
996 ‎‡2 ISNI|0000000496328667‏
996 ‎‡2 DNB|117303623‏
996 ‎‡2 NII|DA02068118‏
996 ‎‡2 PLWABN|9810644235205606‏
996 ‎‡2 PTBNP|1207919‏
996 ‎‡2 DNB|1169606806‏
996 ‎‡2 ISNI|0000000013231028‏
996 ‎‡2 NUKAT|n 2014045193‏
996 ‎‡2 LC|n 91069354‏
996 ‎‡2 ISNI|0000000368129612‏
996 ‎‡2 N6I|vtls000073868‏
996 ‎‡2 SUDOC|087584913‏
996 ‎‡2 SUDOC|203117344‏
996 ‎‡2 NUKAT|n 2017077052‏
996 ‎‡2 J9U|987007425688505171‏
996 ‎‡2 NUKAT|n 2022062299‏
996 ‎‡2 DNB|123514568‏
996 ‎‡2 BNF|15603393‏
996 ‎‡2 DNB|117303593‏
996 ‎‡2 DNB|117303577‏
996 ‎‡2 RERO|A003968654‏
996 ‎‡2 BAV|495_200878‏
996 ‎‡2 DNB|1260051285‏
996 ‎‡2 DNB|1329326911‏
996 ‎‡2 NUKAT|n 2002072680‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏
998 ‎‡a Werner, Ricardo Niklas‏ ‎‡2 DNB|1273764137‏ ‎‡3 standard number‏